Lung cancer is the leading cause of cancer deaths worldwide.

Size: px
Start display at page:

Download "Lung cancer is the leading cause of cancer deaths worldwide."

Transcription

1 ORIGINAL ARTICLE Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non Small-Cell Lung Cancer Jung-Jyh Hung, MD, PhD,* Wen-Juei Jeng, MD, Wen-Hu Hsu, MD,* Teh-Ying Chou, MD, PhD, Biing-Shiun Huang, MD, PhD,* and Yu-Chung Wu, MD* Objective: This study investigated the factors predicting recurrence and death in patients with resected stage-i non small-cell lung cancers according to the 7th edition of tumor, node, metastasis (TNM) classification for lung cancer. Methods: All patients undergoing surgical resection for pathological stage-i non small-cell lung cancers at Taipei Veterans General Hospital between 1980 and 2000 were retrospectively reviewed. Those undergoing sublobar resection were excluded. The factors predicting overall survival (OS), overall recurrence, local recurrence, and distant metastasis were investigated. Results: A total of 756 patients were eligible. The 5-year OS rate and probability of freedom from recurrence were 57.3% and 70.2%, respectively. The 2-year local-recurrence free and distant-metastasis free rates were 90.7% and 82.1%, respectively. In multivariable analysis, the new T descriptor (T1a, T1b, and T2a) was the common factor that significantly affected OS (p = 0.003), overall recurrence (p = 0.004), and distant metastasis (p < 0.001). Smoking index more than 20, and number of mediastinal lymph nodes dissected/sampled of 15 or fewer were common factors that significantly predicted worse OS (p < 0.001, p < 0.001, respectively), lower probability of freedom from overall recurrence (p = 0.025, p = 0.009, respectively), and higher risk of local recurrence (p < 0.001, p = 0.030, respectively). Non squamous-cell histology predicted higher risk of distant metastasis (p = 0.006). Conclusions: Risks of death and recurrence increase as the T descriptor upgrades in the new TNM system. The combination of risk factors can be used to identify high-risk subgroups of local recurrence and distant metastasis. Key Words: Non small-cell lung cancer, Survival, Local recurrence, Distant metastasis. (J Thorac Oncol. 2012;7: ) *Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan; Department of Internal Medicine, Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Taipei, Taiwan; and Institute of Clinical Medicine, National Yang-Ming University, and Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Disclosure: The authors declare no conflict of interest. Address for correspondence: Yu-Chung Wu, MD, Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan. wuyc@vghtpe.gov.tw. Copyright 2012 by the International Association for the Study of Lung Cancer ISSN: /12/ Journal of Thoracic Oncology Volume 7, Number 7, July 2012 Lung cancer is the leading cause of cancer deaths worldwide. Surgical resection is the treatment of choice for early-stage non small-cell lung cancer (NSCLC). 1,2 Five-year survival in patients with resected stage-i NSCLC according to the 6th edition of the TNM classification (TNM 6) for lung cancer 3 ranges between 55% and 80%. 4 7 Tumor recurrence is the most common cause of disease failure after surgical resection. 5 9 Postrecurrence survival in resected stage-i NSCLC is poor The 7th edition of the TNM classification (TNM 7) for lung cancer was published in ,13 In the TNM 7, the T1 descriptor has been classified into T1a ( 2 cm) and T1b (>2 to 3 cm), whereas size-based T2 descriptor has been classified into T2a (>3 to 5 cm), T2b (>5 to 7 cm), and T3 (>7 cm). 14 Stage-I NSCLC was subdivided into IA (T1aN0M0 and T1bN0M0) and IB (T2aN0M0). 15 T2bN0M0 and T3N0M0 were classified as stage IIA and stage IIB, respectively. 15 Although some randomized clinical trials have evaluated the role of adjuvant chemotherapy in patients with resected stage-i NSCLC, the benefits remain uncertain Only a few studies reported the survival and patterns of recurrence in resected stage-i NSCLC (TNM 7) in the literature. The risk factors separately predicting local recurrence and distant metastasis in resected stage-i (TNM 7) NSCLC have not been demonstrated. Identification of factors associated with the development of local recurrence or distant metastasis after surgical resection may be useful to stratify patients with higher risks in the future design of clinical trials for aggressive adjuvant therapy. In this report, we focused on the analysis of the factors predicting survival, local recurrence, and distant metastasis in patients with stage-i NSCLC (TNM 7) after complete resection. PATIENTS AND METHODS All patients who underwent surgical resection for pathological stage-i NSCLC at Taipei Veterans General Hospital between January 1980 and December 2000 were reviewed. Those undergoing sublobar resection were excluded. A total of 916 patients were eligible according to the TNM 6 for lung cancer. Among them 756 patients (82.5%) were reclassified as pathological stage-i NSCLC according to the TNM 7 for lung cancer, and were included in this retrospective study. This study has been approved by the Institutional Review Board of Taipei Veterans General Hospital. 1115

2 Hung et al. Journal of Thoracic Oncology Volume 7, Number 7, July 2012 The preoperative staging work-up, including chest and upper-abdomen computed tomographic scans, bronchoscopic examination, and nuclear medicine survey (bone and brain), was done as previously described. 19,20 Mediastinoscopy was not a routine preoperative staging procedure, and was performed only when enlarged mediastinal lymph nodes (LNs) (diameter > 1.0 cm) were shown by the computed tomographic scan. During the study period, positron emission tomography scan was not available as a staging modality. All patients underwent complete resection of lung cancer with mediastinal LN dissection/sampling as previously described. 19,20 None of the patients had received adjuvant therapy after initial surgical resection. Histological typing was determined according to the World Health Organization classification, 21 and all the histological cases were reviewed. Determination of disease stages were based on the TNM classification (7th edition) of the American Joint Committee on Cancer and the International Union Against Cancer. 12,13 All patients were followed up at our outpatient department as previously described. 19,20 Secondary primary lung cancer was differentiated from recurrent NSCLC according to the criteria proposed by Martini and Melamed. 5,22 Local recurrence was defined as tumor recurrence in contiguous anatomical sites, including the ipsilateral hemithorax and mediastinum after surgical resection. Distant recurrence was defined as tumor recurrence in the contralateral lung or outside the hemithorax and mediastinum after surgical resection. To investigate their impact on overall survival (OS), overall recurrence, local recurrence, and distant metastasis, clinicopathologic factors were analyzed in univariate and multivariate analyses. The length of OS is defined as the interval between the date of surgical resection and the date of either death or the last follow-up. Pattern of recurrence is defined as all recurrences (including local recurrence, distant metastasis, or both local and distant) discovered from the initial operation to death or last follow-up. Time to recurrence (the period of freedom from recurrence) is defined as the interval between the date of surgical resection and the date of the first recurrence or the last follow-up. An observation was censored at the last follow-up session when the patient was alive with recurrence-free status, or had died without recurrence. In the analysis of prognostic factors for time to recurrence, recurrence (local or distant) is defined by the first recurrence. If both local and distant diseases are noted within a time frame of 3 months, they will be defined as both local recurrence and distant metastasis. Patients with both local recurrence and distant metastasis were excluded from analysis of freedom from local recurrence or distant metastasis. The OS and probabilities of freedom from overall recurrence, local recurrence, and distant metastasis were calculated by the Kaplan-Meier method. 23 To compare between the groups with respect to categorical and continuous variables, the χ 2 test or the independent sample t test was used as appropriate. Univariate and multivariate analyses were performed by means of the Cox proportional hazards model using SPSS software (version 16.0; SPSS, Chicago, IL). Only variables with p < 0.1 after the univariate analysis were entered into the multivariate analysis. Statistical significance was defined as p < RESULTS Among the 916 surgically resected stage-i NSCLC patients (TNM 6), 756 (82.5%) patients were reclassified as pathological stage I, 108 (11.8%) were as stage IIA, and 52 (5.7%) were as stage IIB according to the TNM 7. Stage distribution for both TNM 6 and TNM 7 is listed in Table 1. Conversion from the 6 th to the 7th edition resulted in 17.5% stage migration. The median follow-up time for all the 756 surgically resected stage-i NSCLC (TNM 7) patients was 67.7 months (mean, 75.7 ± 57.0 months). The characteristics of these 756 patients are listed in Table 2. Nineteen postoperative deaths (2.5%) occurred. The 5- and 10-year OS rates were 57.3% and 36.4%, respectively (Fig. 1A). The 5- and 10-year disease-free survival rates were 55.1% and 36.1%, respectively (Fig. 1B). Among these 756 patients, 509 (67.3%) were free of tumor recurrence, 213 (28.2%) developed recurrence, and 34 patients (4.5%) were with unknown recurrent status during follow-up. The 5- and 10-year probabilities from recurrence were 70.2 % and 69.4%, respectively (Fig. 2A). The relationship between disease-free status and clinicopathological variables is shown in Table 3. The recurrent group consisted of more T2a tumor (p = 0.004), and a higher frequency of patients with 15 or lesser mediastinal LNs dissected/sampled (p = 0.030). As the T descriptors upgrade from T1a, T1b, to T2a, tumor recurrence rates increase from 19.5% (31/159), 29.6% (66/223), to 34.1% (116/224), respectively. The patterns of recurrence included local recurrence only in 51 patients (23.9%), distant metastasis only in 126 (59.2%), and both local recurrence and distant metastasis in 36 patients (16.9%). The relationship between pattern of recurrence (local recurrence only or distant metastasis only) and clinicopathological variables is shown in Table 4. As compared with the distant-metastasis only group, the local-recurrence only group consisted of more squamous cell carcinoma (p = 0.013), a higher frequency of patients with smoking index greater than 20 pack-years (p = 0.015), and a higher frequency of T1a and T1b tumors (p = 0.048). The distant-metastasis only group consisted of more never smokers, more adenocarcinomas, and a higher frequency of T2a tumors. TABLE 1. Change of Stage Distribution According to the TNM Classification, 6th and 7th Editions Stage 6th Edition TNM TNM Classification 7th Edition No. of Patients Stage TNM No. of Patients Stage IA T1N0M0 406 Stage IA T1aN0M0 168 T1bN0M0 238 Stage IB T2N0M0 510 Stage IB T2aN0M0 350 Stage IIA T2bN0M0 108 Stage IIB T3N0M Copyright 2012 by the International Association for the Study of Lung Cancer

3 Journal of Thoracic Oncology Volume 7, Number 7, July 2012 Predictors of Death and Recurrence in Stage I Lung Cancer TABLE 2. Characteristics of 756 Patients with Resected Stage-I Non Small-Cell Lung Cancer Variables Data Age, yrs (mean ± SD) 65.1 ± 9.4 Sex, no. (%) Male 589 (77.9) Female 167 (22.1) Sm oking index, pack-years (median [IQR]) 20.0 ( ) Tumor location, no. (%) Left lung 185 (24.5) Right lung 571 (75.5) Histological type, no. (%) Squamous cell carcinoma 287 (38.0) Adenocarcinoma 357 (47.2) Bronchioloalveolar carcinoma 49 (6.5) Large cell carcinoma 57 (7.5) Adenosquamous carcinoma 6 (0.8) Extent of pulmonary resection, no. (%) Lobectomy 603 (79.7) Bilobectomy 78 (10.4) Pneumonectomy 75 (9.9) T status, no. (%) T1a 168 (22.2) T1b 238 (31.5) T2a 350 (46.3) Visceral pleural invasion, no. (%) Absent 565 (74.7) Present 155 (20.5) Unknown 36 (4.8) Nu mber of LNs dissected/sampled 15.3 ± 9.7 (mean ± SD) IQR, interquartile range; LN, lymph node. Overall Survival Univariate analysis indicated that older age (p < 0.001), male sex (p < 0.001), higher smoking index (p < 0.001), squamous cell carcinoma (p = 0.003), bilobectomy or pneumonectomy (p = 0.015), and 15 or fewer mediastinal LNs dissected/sampled (p = 0.001) were predictors of worse OS (Table 5). As compared with T1a, T1b (p = 0.001) and T2a (p < 0.001) were significant predictors of worse OS. Order age (p < 0.001), higher smoking index (p < 0.001), bilobectomy or pneumonectomy (p = 0.039), and 15 or lesser mediastinal LNs dissected/sampled (p < 0.001) were still significant predictors of worse OS in multivariate analysis (Table 6). As compared with T1a, T1b (p = 0.010) and T2a (p = 0.001) were significant predictors of worse OS. Overall Recurrence Univariate analysis indicated that higher smoking index (p = 0.035) and number of mediastinal LNs dissected/sampled being 15 or fewer (p = 0.023) were predictors of lower probability of freedom from recurrence (Table 5). As compared with T1a, T1b (p = 0.018) and T2a (p < 0.001) were significant predictors of lower probability of freedom from recurrence. FIGURE 1. Cumulative probability of (A) overall survival and (B) disease-free survival in 756 patients with resected stage-i non small-cell lung cancer. Higher smoking index (p = 0.025), advanced T status (p = 0.004), and number of mediastinal LNs dissected/sampled less than or equal to 15 (p = 0.009) were still significant predictors of lower probability of freedom from recurrence in multivariate analysis (Table 6). As compared with T1a, T1b (p = 0.028) and T2a (p = 0.001) were significant predictors of lower probability of freedom from recurrence. Local Recurrence For analysis of time to recurrence, recurrence (local or distant) is defined by the first recurrence. Local recurrence Copyright 2012 by the International Association for the Study of Lung Cancer 1117

4 Hung et al. Journal of Thoracic Oncology Volume 7, Number 7, July 2012 TABLE 3. Relationship Between Disease-Free Status and Clinicopathologic Variables in Patients of Pathological Stage I Non Small-Cell Lung Cancer Variables Disease-Free Status No Recurrence (n = 509) With Recurrence (n = 213) p Value Age, yrs (mean ± SD) 65.1 ± ± Sex, no. (%) Male 392 (77.0) 169 (79.3) Female 117 (23.0) 44 (20.7) Smoking index, pack-years, no. (%) a Never 177 (37.2) 63 (31.2) (17.8) 29 (14.3) > (45.0) 110 (54.5) Histological type, no. (%) Squamous cell carcinoma 201 (39.5) 73 (34.3) Adenocarcinoma 266 (52.2) 121 (56.8) Others 42 (8.3) 19 (8.9) T descriptor, no. (%) T1a 128 (25.1) 31 (14.5) T1b 157 (30.8) 66 (31.0) T2a 224 (44.1) 116 (54.5) Extent of pulmonary resection, no. (%) Lobectomy 400 (78.6) 173 (81.2) Pneumonectomy or bilobectomy 109 (21.4) 40 (18.8) Visceral pleural invasion, no. (%) a Absent 381 (79.0) 158 (77.1) Present 101 (21.0) 47 (22.9) Number of LNs dissected/sampled, no. (%) a (53.8) 132 (62.6) > (46.2) 79 (37.4) a Data are lacking in some patients for these variables. LN, lymph node. only, distant metastasis only, and both local recurrence and distant metastasis were identified in 59, 131, and 19 patients, respectively. The 2- and 5-year local-recurrence free rates were 90.7% and 87.8%, respectively (Fig. 2B). Univariate analysis indicated that higher smoking index (p = 0.001) was a significant predictor of lower probability of freedom from local recurrence (Table 5). Number of mediastinal LNs dissected/sampled less than or equal to 15 (p = 0.072) tended to be a significant predictor of local recurrence. Higher smoking index (p < 0.001) and number of mediastinal LNs dissected/ sampled less than or equal to 15 (p = 0.030) were significant predictors of lower probability of freedom from local recurrence in multivariate analysis (Table 6). FIGURE 2. Cumulative probability of freedom from (A) overall recurrence, (B) local recurrence, and (C) distant metastasis in 756 patients with resected stage-i non small cell lung cancer. Distant Metastasis The 2- and 5-year distant-metastasis free rates were 82.1% and 78.3%, respectively (Fig. 2C). Univariate analysis indicated that adenocarcinoma (p = 0.014) and T2a (p < 0.001) were significant predictors of lower probability of freedom from distant metastasis (Table 5). T1b (p = 0.084) and number of mediastinal LNs dissected/sampled less that 1118 Copyright 2012 by the International Association for the Study of Lung Cancer

5 Journal of Thoracic Oncology Volume 7, Number 7, July 2012 Predictors of Death and Recurrence in Stage I Lung Cancer TABLE 4. Relationship Between Pattern of Recurrence and Clinicopathologic Variables in Patients of Pathological Stage-I Non Small-Cell Lung Cancer Variables Pattern of Recurrence Local Recurrence Only (n = 51) Distant Metastasis Only (n = 126) p Value Age, yrs (mean ± SD) 63.0 ± ± Age at recurrence, 64.6 ± ± years (mean ± SD) Sex, no. (%) Male 43 (84.3) 97 (77.0) Female 8 (15.7) 29 (23.0) Smoking index, pack-years, no. (%) a Never 10 (20.4) 46 (39.0) (10.2) 19 (16.1) >20 34 (69.4) 53 (44.9) Histological type, no. (%) Squamous cell 25 (49.0) 33 (26.2) carcinoma Adenocarcinoma 22 (43.1) 80 (63.5) Others 4 (7.9) 13 (10.3) T descriptor, no. (%) T1a 9 (17.7) 16 (12.7) T1b 22 (43.1) 35 (27.8) T2a 20 (39.2) 75 (59.5) Extent of pulmonary resection, no. (%) Lobectomy 38 (74.5) 105 (83.3) Pneumonectomy or bilobectomy 13 (25.5) 21 (16.7) Visceral pleural invasion, no. (%) Absent 38 (74.5) 88 (69.8) Present 11 (21.6) 33 (26.2) Unknown 2 (3.9) 5 (4.0) Number of LNs dissected/sampled, no. (%)* (66.7) 79 (63.2) >15 17 (33.3) 46 (36.8) a Data are lacking in some patients for these variables. LN, lymph node. or equal to 15 (p = 0.057) tended to be significant predictors for distant metastasis. Adenocarcinoma (p = 0.002) and T2a (p < 0.001) were still significant predictors of lower probability of freedom from distant metastasis in multivariate analysis (Table 6). Application of the Number of Risk Factors in Predicting Local Recurrence and Distant Metastasis To examine the cumulative predictive value of local recurrence, a smoking index of more than 20 pack-years and number of mediastinal LNs dissected/sampled equal to or lesser than 15 were used as risk predictors for local recurrence. We divided all patients into three groups according to the number of positive risk predictors: none positive (group 1), one positive (group 2), and two positive (group 3). Kaplan-Meier analysis showed that the possibility of local recurrence was significantly associated with the number of risk predictors (Fig. 3A). Patients with two positive risk predictors had the highest possibility of local recurrence. To examine the cumulative effect predicting distant metastasis, non squamous-cell histology and T2a were used as risk predictors for distant metastasis. We divided all patients into three groups according to the number of positive risk predictors: none or one positive (group 1), two positive (group 2), and three predictors positive (group 3). Kaplan-Meier analysis showed that patients with both risk predictors had significantly higher possibility of distant metastasis (Fig. 3B). DISCUSSION This study investigated the common and distinct factors predicting local recurrence, distant metastasis, and death in patients with completely resected pathological stage-i NSCLC (TNM 7). The extent of pulmonary resection for T1N0 NSCLC remains controversial. The Lung Cancer Study Group randomized controlled trial recommended lobectomy over limited resection for T1N0 NSCLC. 24 Patients undergoing limited resection had significantly increased local recurrence rate than those undergoing lobectomy. 24 However, several recent studies showed that limited resection may be equally effective for the treatment of stage-ia tumors with a diameter of 2 cm or lesser Exclusion of patients undergoing sublobar resection in our cohort avoided the controversies and reduced the possibility of local recurrence because of inadequate resection margin. The T descriptor was a common factor that significantly predicted OS, overall recurrence, and distant metastasis in our study. The smoking index and number of mediastinal LNs dissected/sampled being 15 or fewer were factors significantly predicting OS, overall recurrence, and local recurrence. Non squamous-cell histology was a factor predicting distant metastasis. The TNM 7 has been published in 2009, 12,13 and stage-i NSCLC was reclassified as IA (T1aN0M0, T1bN0M0) and IB (T2aN0M0). Stage IA was not changed to that of TNM 6, whereas stage IB was restricted to T2aN0M0. T2bN0M0 was reclassified as stage IIA. Pepek et al. 28 reported 15.1% stage migration of stage-i NSCLC (TNM 6). Maeda et al. 29 reported 6.8% stage migration of stage-i NSCLC (TNM 6). In our study, 108 patients (11.8%) of T2bN0M0 were restaged as stage IIA, and 52 patients (5.7%) of T3N0M0 were regrouped as stage IIB. Conversion from TNM 6 to TNM 7 resulted in 17.5% stage migration. The prognostic factors of stage-i NSCLC (TNM 6) have been widely reported in the literature. 5 7,30,31 However, only several studies reported the prognostic factors of stage-i NSCLC (TNM 7). 29,32 In the report by Maeda et al year OS rates for stage IA and IB (TNM 7) were 89.9% and 72.3%, respectively. They also demonstrated that older age, intratumoral vascular invasion, and visceral pleural invasion were poor prognostic factors in stage-ib NSCLC. 29 In the current study, we investigated the prognostic factors of stage-i NSCLC (TNM 7). The factors predicting poor OS included order age, higher smoking index, bilobectomy or pneumonectomy, T1b or T2a, and number of LNs dissected/sampled being 15 or fewer. Copyright 2012 by the International Association for the Study of Lung Cancer 1119

6 Hung et al. Journal of Thoracic Oncology Volume 7, Number 7, July 2012 TABLE 5. Univariate Analysis of Overall Survival, Cancer-Specific Survival, Local Recurrence and Distant Metastasis in 756 Patients with Resected Stage-I Non Small-Cell Lung Cancer Variables Overall Survival Overall Recurrence Local Recurrence Distant Metastasis HR 95% CI p Value HR 95% CI p Value HR 95% CI p Value HR 95% CI p Value Age, yrs a < Sex Female Male < Smoking index, < pack-years Never > < Location Left lung Right lung Histological type Squamous cell carcinoma Adenocarcinoma Others Extent of pulmonary resection Lobectomy Bilobectomy or pneumonectomy T status <0.001 < T1a T1b T2a < < < Visceral pleural invasion Absent Present Number of LNs dissected/sampled > a The HR associated with age is that the increase in hazard is associated with a 1-year increase in age. Bold indicates significance. HR, hazard ratio; CI, confidence interval; LN, lymph node. The 5-year recurrence rate in stage-i NSCLC (TNM 6) ranges between 76% and 85%. 5,30,33 Maeda et al. 34,35 reported that the 5-year recurrence-free rate in patients with stage-ia NSCLC (TNM 7) ranges between 84% to 87%. In another article by Maeda et al. 32 they report that 5-year recurrence-free rate in patients with stage-i NSCLC (TNM 7) was 84.2%. In the current study, the 5-year recurrence-free rate was 70.2%. The factors predicting overall recurrence included smoking index more than 20, T1b or T2a, and number of LNs dissected/ sampled no more than 15. We also examined recurrence-free rates in local recurrence and distant metastasis separately. The 2- and 5-year local recurrence-free rates were 90.2% and 86.8%, respectively. The 2- and 5-year distant metastasis-free rates were 81.2% and 77.6%, respectively. The localrecurrence free rate was higher than distant-metastasis free rate. We showed that the recurrent group consisted of more T2a tumor and a higher frequency of patients with number of mediastinal LNs dissected/sampled being 15 or fewer. We further examined the relationship between local recurrence and distant metastasis. The local-recurrence only group consisted of more squamous cell carcinoma, a higher frequency of patients with smoking index greater than 20 pack-years, and a higher frequency of T1a and T1b tumors. The distantmetastasis only group consisted of more never smokers, more adenocarcinomas, and a higher frequency of T2a tumors. The predictors for recurrence in resected stage-i NSCLC (TNM 6) has been well demonstrated in the literature. 5,30,33 However, only few studies evaluated the risk factors 1120 Copyright 2012 by the International Association for the Study of Lung Cancer

7 Journal of Thoracic Oncology Volume 7, Number 7, July 2012 Predictors of Death and Recurrence in Stage I Lung Cancer TABLE 6. Multivariate Analysis of Overall Survival, Cancer- Specific Survival, Local Recurrence and Distant Metastasis in 756 Patients with Resected Stage-I Non Small-Cell Lung Cancer Variables HR 95% CI p value Overall survival Age, yrs a <0.001 Smoking index, pack-years <0.001 Never > <0.001 Extent of pulmonary resection Lobectomy 1 Bilobectomy or pneumonectomy T status T1a 1 T1b T2a Number of LNs dissected/sampled 15 1 > <0.001 Overall recurrence Smoking index, pack-years Never > T status T1a 1 T1b T2a Number of LNs dissected/sampled 15 1 > Local recurrence Smoking index, pack-years <0.001 Never > Number of LNs dissected/sampled 15 1 > Distant metastasis Histological type Squamous cell carcinoma 1 Adenocarcinoma Others T status <0.001 T1a 1 T1b T2a <0.001 a The HR associated with age is that the increase in hazard is associated with a 1-year increase in age. HR, hazard ratio; CI, confidence interval; LN, lymph node. for local recurrence and distant metastasis separately. Sawyer et al. 30 reported that the number of LNs dissected being less than 15, and T2 tumor were the factors predicting local recurrence in resected stage-i NSCLC (TNM 6). Tumor size of more than 5 cm and nonsquamous histology predicted a poor distant-metastasis free rate in resected stage-i NSCLC. 30 The predictors for recurrence in resected stage-i NSCLC (TNM 7) has not been widely investigated in the literature. Reports by Maeda et al. 32,35 have demonstrated that histologic differentiation, intratumoral vascular invasion, and visceral of pleural invasion were significant predictors for recurrence in stage-i NSCLC (TNM 7). In our study, the predictors of local recurrence or distant metastasis were examined separately. The factors predicting local recurrence included a smoking index more than 20 and the number of LNs dissected/sampled being 15 or lesser. The factors predicting distant metastasis included non squamous-cell carcinoma and T2a. We further developed a model to stratify high-risk subgroups of local recurrence and distant metastasis by using a combination of distinct risk factors. The possibility of local recurrence was significantly associated with increased number of risk predictors. Patients with smoking index more than 20 and number of LNs dissected/ sampled being 15 or fewer had the highest possibility of local recurrence. Although the possibility of distant metastasis was not associated with increased number of risk predictors (nonsquamous-cell carcinoma or T2a), the group of patients with both risk factors had a significantly higher possibility of distant metastasis. Our results showed that the new T descriptor (T1a, T1b, and T2a) in TNM 7 was a significant factor predicting OS and overall recurrence in stage-i NSCLC. As the T descriptor (T1a, T1b, and T2a) upgrades, tumor-recurrence rates also increase (20%, 30%, and 34%). Furthermore, the new T descriptor predicts distant metastasis in stage-i NSCLC. Increase of risks in death, recurrence, and distant metastasis could be predicted as T descriptor upgrades in the new TNM system. Cigarette smoking has been shown to be a prognostic factor in patients with NSCLC in the literature Hanagiri et al. 36 reported that smoking was a significant postoperative prognostic factor in patients with NSCLC. Bryant et al. 37 reported that a 5-year survival rate was significantly better for never smokers compared to smokers in stage-i NSCLC (TNM 6). Maeda et al. 38 reported that OS and recurrence-free survival in never smokers were significantly better than those of ever smokers in patients with stage-i NSCLC (TNM 7). These authors 39 also discovered that a greater smoking extent was associated with the presence of solid components in stage-i lung adenocarcinoma, which may have more aggressive biological features resulting in poorer outcomes. In our study, smoking index was a significant prognostic factor for OS and overall recurrence, and a predictor of local recurrence. The number of mediastinal LNs dissected/sampled alternatively represents the quality of lymphadenectomy, and affects the survival rate for patients with resected stage-i NSCLC. 19,31 Sawyer et al. 30 reported that factors predicting poor OS in resected stage-i NSCLC (TNM 6) included Copyright 2012 by the International Association for the Study of Lung Cancer 1121

8 Hung et al. Journal of Thoracic Oncology Volume 7, Number 7, July 2012 FIGURE 3. A, Kaplan-Meier analysis (log-rank test) for local recurrence. The patients were divided into three groups according to number of positive risk predictors (smoking index > 20 and number of mediastinal lymph nodes dissected/sampled 15): none positive (group 1), one positive (group 2), and two positive (group 3). The possibility of local recurrence increased as the number of risk predictors increased. B, Kaplan- Meier analysis (log-rank test) for distant metastasis. The patients were divided into three groups according to number of positive risk predictors (nonsquamous cell histology and T2a): none positive (group 1), one positive (group 2), and two positive (group 3). Patients with both positive risk predictors had higher possibility of distant metastasis. fewer than 15 LNs dissected and a tumor size greater than 3 cm. Varlotto et al. 31 also reported that lymphadenectomy was associated with improved OS and disease-free survival in resected stage-i NSCLC (TNM 6). The current study showed that number of mediastinal LNs dissected/sampled was a predictor of OS and overall recurrence in stage-i NSCLC (TNM 7). Furthermore, we showed that number of LNs dissected/ sampled was also a predictor of local recurrence in stage-i NSCLC (TNM 7). There are some limitations and biases of this study that should be mentioned. As a retrospective, single-institute study, patient-selection bias and time-trend bias were inevitable. Although the patients were not selected according to location (right or left side), only 24% of the tumors were left-sided in our study. That may be a result of the bias from conducting a single-institute study. However, we showed that location (right versus left side) did not influence OS and probability of freedom from recurrence. As a retrospective study, it was difficult to obtain performance status from the charts. Although performance status is clearly an important factor in stage-iv NSCLC, its importance in stage-i disease has not yet been established. Lack of data about performance status might have little significance in the analysis of death and recurrence in our study. Furthermore, the fact that the predictors demonstrated in our study were not all consistent with other reports highlights the possibility of false positive findings. Prospective multi-institutional studies are mandatory to further validate the predictors of recurrence and death in resected stage-i NSCLC (TNM 7). The new T descriptor was a common factor predicting OS, overall recurrence, and distant metastasis in resected stage-i NSCLC of the new TNM 7 system. Smoking index and number of mediastinal LNs dissected/sampled being 15 or fewer were predictors of local recurrence, whereas non squamous-cell histology and T2a were predictors of distant metastasis. The combination of distinct risk factors is useful in specifically predicting local recurrence or distant metastasis. A risk-guided strategy focusing on OS, overall recurrence, local recurrence and/or distant metastasis could be used in the future design of clinical trials for adjuvant chemotherapy and/ or radiation therapy. ACKNOWLEDGMENTS The authors thank Dr. Liang-Shun Wang of Shuang Ho Hospital, Taipei, Taiwan for contributing to this article Copyright 2012 by the International Association for the Study of Lung Cancer

9 Journal of Thoracic Oncology Volume 7, Number 7, July 2012 Predictors of Death and Recurrence in Stage I Lung Cancer They also thank Mr. Jung-Hsing Lin for his assistance in data collection. Supported in part by National Science Council (NSC B ) (JJ Hung), National Science Council (NSC B MY2) (YC Wu), Center of Excellence for Cancer Research at Taipei Veterans General Hospital (DOH100-TD-C ) (YC Wu), Yen Tjing Ling Medical Foundation (CI ) (JJ Hung) and Taipei Veterans General Hospital (V101B-038) (JJ Hung). REFERENCES 1. Spira A Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350: Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K; American College of Chest Physicians. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2 nd edition). Chest 2007;132(3 Suppl):234S 242S. 3. Sobin L, Wittekind Ch, eds. TNM Classification of Malignant Tumors, 6th Ed. New York: Wiley-Liss, Pp Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111: Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109: Harpole DH Jr, Herndon JE 2nd, Young WG Jr, Wolfe WG, Sabiston DC Jr. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76: Jones DR, Daniel TM, Denlinger CE, Rundall BK, Smolkin ME, Wick MR. Stage IB nonsmall cell lung cancers: are they all the same? Ann Thorac Surg 2006;81: ; discussion Nakagawa T, Okumura N, Ohata K, Igai H, Matsuoka T, Kameyama K. Postrecurrence survival in patients with stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2008;34: Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent nonsmallcell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007;83: Hung JJ, Hsu WH, Hsieh CC, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009;64: Hung JJ, Jeng WJ, Hsu WH, et al. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis. Thorax 2010;65: American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York: Springer, International Union Against Cancer. TNM Classification of Malignant Tumours. 7 th ed. Oxford, UK: Wiley-Blackwell, Rami-Porta R, Ball D, Crowley J, et al.; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2: Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2: Strauss GM, Herndon JE II, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract 7007]. J Clin Oncol 2006;24:365S. 17. Strauss GM, Herndon JE 2 nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26: Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010;28: Hung JJ, Wang CY, Huang MH, Huang BS, Hsu WH, Wu YC. Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival. J Thorac Cardiovasc Surg 2007;134: Hung JJ, Jeng WJ, Hsu WH, et al. Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm. Eur Respir J 2010;36: Travis WD, Colby TB, Corrin B, et al. Histological typing of tumors of lung and pleura. In LH Sobin (Ed.) World Health Organization International Classification of Tumours, 3rd Ed. New York: Springer- Verlag, 1999: Martini N Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975;70: Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53: Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;60: El-Sherif A, Gooding WE, Santos R, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg 2006;82: Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis. Br J Cancer 2005;92: Wisnivesky JP, Henschke CI, Swanson S, et al. Limited resection for the treatment of patients with stage IA lung cancer. Ann Surg 2010;251: Pepek JM, Chino JP, Marks LB, et al. How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems. J Thorac Oncol 2011;6: Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Poor prognostic factors in patients with stage IB non-small cell lung cancer according to the seventh edition TNM classification. Chest 2011;139: Sawyer TE, Bonner JA, Gould PM, Deschamps C, Lange CM, Li H. Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials. Int J Radiat Oncol Biol Phys 1999;45: Varlotto JM, Recht A, Nikolov M, Flickinger JC, Decamp MM. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Cancer 2009;115: Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. Chest 2011;140: Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, Decamp MM. Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer. Cancer 2009;115: Maeda R, Yoshida J, Ishii G, et al. Long-term outcome and late recurrence in patients with completely resected stage IA non-small cell lung cancer. J Thorac Oncol 2010;5: Maeda R, Yoshida J, Ishii G, et al. Long-term survival and risk factors for recurrence in stage I non-small cell lung cancer patients with tumors up to 3 cm in maximum dimension. Chest 2010;138: Hanagiri T, Sugio K, Mizukami M, et al. Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non-small Cell Lung Cancer. J Thorac Oncol 2008;3: Bryant A Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop nonsmall cell lung cancer. Chest 2007;132: Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. The prognostic impact of cigarette smoking on patients with non-small cell lung cancer. J Thorac Oncol 2011;6: Maeda R, Ishii G, Yoshida J, Hishida T, Nishimura M, Nagai K. Influence of cigarette smoking on histological subtypes of stage I lung adenocarcinoma. J Thorac Oncol 2011;6: Copyright 2012 by the International Association for the Study of Lung Cancer 1123

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis < A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay

More information

Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer

Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer CHEST Original Research Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer Jung-Jyh Hung, MD, PhD ; Wen-Juei Jeng, MD ; Wen-Hu

More information

Lung cancer is a prevalent health problem worldwide. It is the leading cause

Lung cancer is a prevalent health problem worldwide. It is the leading cause Prognostic factors in resected stage I non small cell lung cancer with a diameter of 3 cm or less: Visceral pleural invasion did not influence overall and disease-free survival Jung-Jyh Hung, MD, a,b Chien-Ying

More information

Lung cancer is the main cause of cancer-related death worldwide.

Lung cancer is the main cause of cancer-related death worldwide. Original Article Prognostic Factors of Survival after Recurrence in Patients with Resected Lung Adenocarcinoma Jung-Jyh Hung, MD, PhD,* Yi-Chen Yeh, MD, Wen-Juei Jeng, MD, Hong-Che Chien, MD,* Yu-Chung

More information

Poor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification

Poor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification CHEST Original Research Poor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification LUNG CANCER Ryo Maeda, MD ; Junji Yoshida, MD, PhD

More information

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department

More information

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,

More information

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a

More information

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Prognostic value of visceral pleura invasion in non-small cell lung cancer q European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung

More information

Visceral pleural involvement (VPI) of lung cancer has

Visceral pleural involvement (VPI) of lung cancer has Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,

More information

Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer

Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*

More information

Node-Negative Non-small Cell Lung Cancer

Node-Negative Non-small Cell Lung Cancer ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

The tumor, node, metastasis (TNM) staging system of lung

The tumor, node, metastasis (TNM) staging system of lung ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,

More information

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae

More information

Prognostic factors in curatively resected pathological stage I lung adenocarcinoma

Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,

More information

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans

More information

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,

More information

Accepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD

Accepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:

More information

Standard treatment for pulmonary metastasis of non-small

Standard treatment for pulmonary metastasis of non-small ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji

More information

Prognostic Factors for Post Recurrence Survival in Resected Pathological Stage I Non-small Cell Lung Cancer

Prognostic Factors for Post Recurrence Survival in Resected Pathological Stage I Non-small Cell Lung Cancer Yonago Acta Medica 2017;60:213 219 doi: 10.24563/yam.2017.12.001 Original Article Prognostic Factors for Post Recurrence Survival in Resected Pathological Stage I Non-small Cell Lung Cancer Yasuaki Kubouchi,

More information

Stage IB Nonsmall Cell Lung Cancers: Are They All the Same?

Stage IB Nonsmall Cell Lung Cancers: Are They All the Same? ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,

More information

Visceral pleura invasion (VPI) was adopted as a specific

Visceral pleura invasion (VPI) was adopted as a specific ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,

More information

The roles of adjuvant chemotherapy and thoracic irradiation

The roles of adjuvant chemotherapy and thoracic irradiation Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,

More information

Prognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients

Prognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients 1 Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan 2 Department of Pathology, Research Center for Innovative Oncology, National Cancer Center Hospital East,

More information

The accurate assessment of lymph node involvement is

The accurate assessment of lymph node involvement is ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*

More information

Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy

Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy

More information

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

Despite advances in radiation therapy, chemotherapy, Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer

Despite advances in radiation therapy, chemotherapy, Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer Matthew D. Taylor, MD, Alykhan S. Nagji, MD, Castigliano M. Bhamidipati, DO, MS, Nicholas Theodosakis, BS, Benjamin D. Kozower,

More information

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data CHEST Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data William N. William, Jr, MD; Heather Y. Lin, PhD; J. Jack Lee, PhD; Scott M.

More information

Lung cancer pleural invasion was recognized as a poor prognostic

Lung cancer pleural invasion was recognized as a poor prognostic Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

A comparison of the proposed classifications for the revision of N descriptors for non-small-cell lung cancer

A comparison of the proposed classifications for the revision of N descriptors for non-small-cell lung cancer European Journal of Cardio-Thoracic Surgery 49 (2016) 580 588 doi:10.1093/ejcts/ezv134 Advance Access publication 18 April 2015 ORIGINAL ARTICLE Cite this article as: Lee GD, Kim DK, Moon DH, Joo S, Hwang

More information

In the mid 1970s, visceral pleural invasion (VPI) was included

In the mid 1970s, visceral pleural invasion (VPI) was included ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*

More information

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi

More information

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko Higashiyama, MD, PhD, Tomio Nakayama, MD, PhD,

More information

Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers

Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers European Journal of Cardio-thoracic Surgery 36 (2009) 1031 1036 www.elsevier.com/locate/ejcts Applicability of the revised International Association for the Study of Lung Cancer staging system to operable

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer

Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department

More information

The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer

The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:

More information

An Update: Lung Cancer

An Update: Lung Cancer An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology

More information

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;

More information

Accepted Manuscript. Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD

Accepted Manuscript. Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD Accepted Manuscript Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD PII: S0022-5223(18)31821-X DOI: 10.1016/j.jtcvs.2018.06.069 Reference: YMTC 13198 To appear in: The

More information

Although the international TNM classification system

Although the international TNM classification system Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru

More information

Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis

Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Original Article Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Jingxu Li, Xinguan Yang, Tingting

More information

The 7th Edition of TNM in Lung Cancer.

The 7th Edition of TNM in Lung Cancer. 10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic

More information

Thorax Online First, published on September 23, 2009 as /thx

Thorax Online First, published on September 23, 2009 as /thx Thorax Online First, published on September 23, 2009 as 10.1136/thx.2009.115691 1 Prognostic significance of hypoxia-inducible factor-1α, TWIST1 and Snail expression in resectable non-small cell lung cancer

More information

Prognostic factors in resected pathological N1-stage II non-small cell lung cancer. School of Medicine, National Yang-Ming University, Taipei, Taiwan

Prognostic factors in resected pathological N1-stage II non-small cell lung cancer. School of Medicine, National Yang-Ming University, Taipei, Taiwan ERJ Express. Published on July 26, 2012 as doi: 10.1183/09031936.00058512 Prognostic factors in resected pathological N1-stage II non-small cell lung cancer Chao-Yu Liu, MD 1, Jung-Jyh Hung, MD 1,3, Bing-Yen

More information

Visceral pleural invasion (VPI) of lung cancer has been

Visceral pleural invasion (VPI) of lung cancer has been ORIGINAL ARTICLE Visceral Pleural Invasion Classification in Non Small- Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer: Validation Analysis Based on a

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in

Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in 1 Manuscript type: Original Article DOI: Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in twenty years? A single centre experience Short title: Changes in the

More information

Lung cancer is the most common cause of cancer-related

Lung cancer is the most common cause of cancer-related Original Article Prognostic Factors Based on Clinicopathological Data Among the Patients with Resected Peripheral Squamous Cell Carcinomas of the Lung Tomonari Kinoshita, MD,* Takashi Ohtsuka, MD, PhD,*

More information

Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer

Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer Ann Thorac Cardiovasc Surg 2011; 17: 58 62 Case Report Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer Motoki Yano, MD, Hidefumi Sasaki, MD, Satoru Moriyama, MD, Osamu Kawano MD, Yu

More information

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan

More information

Since the introduction of low-dose helical computed tomography

Since the introduction of low-dose helical computed tomography Original Article Prognostic Impact of Tumor Size Eliminating the Ground Glass Opacity Component Modified Clinical T Descriptors of the Tumor, Node, Metastasis Classification of Lung Cancer Shota Nakamura,

More information

Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule

Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule Original Article Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule Jong Hui Suh 1, Jae Kil Park 2, Youngkyu Moon 2 1 Department of Thoracic & Cardiovascular Surgery,

More information

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,

More information

Lung cancer is now a major cause of death in developed

Lung cancer is now a major cause of death in developed Original Article New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma Naoki Yanagawa, MD, PhD,* Satoshi Shiono, MD, PhD, Masami Abiko,

More information

Lymph node dissection for lung cancer is both an old

Lymph node dissection for lung cancer is both an old LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko

More information

Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non small cell lung cancer

Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non small cell lung cancer Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non small cell lung cancer Terumoto Koike, MD, PhD, a,b Teruaki Koike, MD, PhD, a Katsuo Yoshiya,

More information

Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome

Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome Original Article Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome Chun-Yu Lin 1,2, Ying-Jen Chen 1,2, Meng-Heng Hsieh 2,3, Chih-Wei Wang 2,4,

More information

Surgical resection is the first treatment of choice for

Surgical resection is the first treatment of choice for Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,

More information

Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution

Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Maruyama et al General Thoracic Surgery Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Riichiroh Maruyama, MD Fumihiro

More information

Xiang Hu*, Liang Cao*, Yi Yu. Introduction

Xiang Hu*, Liang Cao*, Yi Yu. Introduction Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang

More information

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,

More information

Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis

Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,

More information

Induction chemotherapy followed by surgical resection

Induction chemotherapy followed by surgical resection Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser

More information

Mediastinal Staging. Samer Kanaan, M.D.

Mediastinal Staging. Samer Kanaan, M.D. Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor

More information

Local Recurrence After Surgery for Early Stage Lung Cancer

Local Recurrence After Surgery for Early Stage Lung Cancer Original Article Local Recurrence After Surgery for Early Stage Lung Cancer An 11-Year Experience With 975 Patients Chris R. Kelsey, MD 1 ; Lawrence B. Marks, MD 2 ; Donna Hollis, MS 3 ; Jessica L. Hubbs,

More information

Should minimally invasive lung adenocarcinoma be transferred from stage IA1 to stage 0 in future updates of the TNM staging system?

Should minimally invasive lung adenocarcinoma be transferred from stage IA1 to stage 0 in future updates of the TNM staging system? Original Article Should minimally invasive lung adenocarcinoma be transferred from stage to stage 0 in future updates of the TNM staging system? Tianxiang Chen 1,2#, Jizhuang Luo 3#, Haiyong Gu 3, Yu Gu

More information

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National

More information

LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II

LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco

More information

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new

More information

Prognosis of recurrent non small cell lung cancer following complete resection

Prognosis of recurrent non small cell lung cancer following complete resection 1300 Prognosis of recurrent non small cell lung cancer following complete resection HIDEFUMI SASAKI, AYUMI SUZUKI, TSUTOMU TATEMATSU, MASAYUKI SHITARA, YU HIKOSAKA, KATSUHIRO OKUDA, SATORU MORIYAMA, MOTOKI

More information

Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival

Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B. Marks, MD, Richard H. Feins, MD, Benjamin

More information

The Itracacies of Staging Patients with Suspected Lung Cancer

The Itracacies of Staging Patients with Suspected Lung Cancer The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung

More information

The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)

The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative

More information

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Yasushi Shintani, MD, hd, a Mitsunori Ohta, MD, hd, a Teruo Iwasaki, MD, hd, a Naoki

More information

Cheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda

Cheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score

More information

NSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy

NSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local

More information

Surgery for early stage NSCLC

Surgery for early stage NSCLC 1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what

More information

Imaging of Lung Cancer: A Review of the 8 th TNM Staging System

Imaging of Lung Cancer: A Review of the 8 th TNM Staging System Imaging of Lung Cancer: A Review of the 8 th TNM Staging System Travis S Henry, MD Associate Professor of Clinical Radiology Cardiac and Pulmonary Imaging Section University of California, San Francisco

More information

Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy

Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L. Chen, MD, MBA, Cindy Yu, MD, and Royce

More information

Small-cell lung cancer (SCLC) represents approximately

Small-cell lung cancer (SCLC) represents approximately Original Article Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn G. Hancock, BS, Daniel J. Boffa, MD,

More information

Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer

Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis

More information

The T4 category of lung cancer is defined by invasion of the

The T4 category of lung cancer is defined by invasion of the Original Article Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category? Shun-ichi Watanabe, MD,* Hisao Asamura,

More information

Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer

Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,

More information

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,

More information

Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma

Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma 244 Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma DAISUKE HOKKA 1, KAZUYA UCHINO 2, KENTA TANE 2, HIROYUKI OGAWA

More information

Multifocal Lung Cancer

Multifocal Lung Cancer Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department

More information

8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC

8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC 8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour

More information

Complete surgical excision remains the greatest potential

Complete surgical excision remains the greatest potential ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

Lung cancer involving neighboring structures is classified

Lung cancer involving neighboring structures is classified GENERAL THORACIC Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro, MD, Takayuki Fukui, MD, Shunzo Hatooka,

More information

Xing Wang *, Shi Yan *, Yaqi Wang, Xiang Li, Chao Lyu, Yuzhao Wang, Jia Wang, Shaolei Li, Lijian Zhang, Yue Yang, Nan Wu. Original Article.

Xing Wang *, Shi Yan *, Yaqi Wang, Xiang Li, Chao Lyu, Yuzhao Wang, Jia Wang, Shaolei Li, Lijian Zhang, Yue Yang, Nan Wu. Original Article. Original Article Adjuvant chemotherapy may improve outcome of patients with non-small-cell lung cancer with metastasis of intrapulmonary lymph nodes after systematic dissection of N1 nodes Xing Wang *,

More information

The lung cancer cure rate is dismal and has. The Effect of Tumor Size on Curability of Stage I Non-small Cell Lung Cancers*

The lung cancer cure rate is dismal and has. The Effect of Tumor Size on Curability of Stage I Non-small Cell Lung Cancers* The Effect of Tumor Size on Curability of Stage I Non-small Cell Lung Cancers* Juan P. Wisnivesky, MD, MPH; David Yankelevitz, MD; and Claudia I. Henschke, PhD, MD, FCCP Objective: The objective of this

More information

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert

More information